211 related articles for article (PubMed ID: 12601765)
1. Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults.
Ben-Yehuda A; Joseph A; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Barenholz Y; Kedar E
J Med Virol; 2003 Apr; 69(4):560-7. PubMed ID: 12601765
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents.
Ben-Yehuda A; Joseph A; Barenholz Y; Zeira E; Even-Chen S; Louria-Hayon I; Babai I; Zakay-Rones Z; Greenbaum E; Galprin I; Glück R; Zurbriggen R; Kedar E
Vaccine; 2003 Jul; 21(23):3169-78. PubMed ID: 12804845
[TBL] [Abstract][Full Text] [Related]
3. A TritonX-100-split virion influenza vaccine is safe and fulfills the committee for proprietary medicinal products (CPMP) recommendations for the European Community for Immunogenicity, in Children, Adults and the Elderly.
Lina B; Fletcher MA; Valette M; Saliou P; Aymard M
Biologicals; 2000 Jun; 28(2):95-103. PubMed ID: 10885616
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine].
Dong PM; Li YQ; Zheng TZ; Jia YP; Li F; Han TW; Qiao RX; Zhang BH
Zhonghua Liu Xing Bing Xue Za Zhi; 2003 Jul; 24(7):570-3. PubMed ID: 12975010
[TBL] [Abstract][Full Text] [Related]
5. Dose sparing with intradermal injection of influenza vaccine.
Kenney RT; Frech SA; Muenz LR; Villar CP; Glenn GM
N Engl J Med; 2004 Nov; 351(22):2295-301. PubMed ID: 15525714
[TBL] [Abstract][Full Text] [Related]
6. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
7. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
[TBL] [Abstract][Full Text] [Related]
8. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
9. A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains.
Babai I; Barenholz Y; Zakay-Rones Z; Greenbaum E; Samira S; Hayon I; Rochman M; Kedar E
Vaccine; 2001 Nov; 20(3-4):505-15. PubMed ID: 11672916
[TBL] [Abstract][Full Text] [Related]
10. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and tolerability of a virosome influenza vaccine compared to split influenza vaccine in patients with sickle cell anemia.
Souza AR; Braga JA; de Paiva TM; Loggetto SR; Azevedo RS; Weckx LY
Vaccine; 2010 Jan; 28(4):1117-20. PubMed ID: 20116631
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a novel influenza subunit vaccine produced in mammalian cell culture.
Szymczakiewicz-Multanowska A; Groth N; Bugarini R; Lattanzi M; Casula D; Hilbert A; Tsai T; Podda A
J Infect Dis; 2009 Sep; 200(6):841-8. PubMed ID: 19673651
[TBL] [Abstract][Full Text] [Related]
13. [Safety and immunogenicity of split vaccines of influenza viruses].
Zhu CL; Fang HH; Zhu FC; Wang YQ; Wu XL; Xue FB; Shen YJ; Lian JZ
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2004 Sep; 18(3):207-9. PubMed ID: 15640848
[TBL] [Abstract][Full Text] [Related]
14. [Study on the safety and immunogenicity of MF59-adjuvanted influenza subunit vaccine in Chinese elderly].
Li RC; Fang HH; Li YP; Liu YP; Nong Y; Huang GB
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Jun; 29(6):548-51. PubMed ID: 19040034
[TBL] [Abstract][Full Text] [Related]
15. Serum antibody responses after intradermal vaccination against influenza.
Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G
N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults.
Van Damme P; Oosterhuis-Kafeja F; Van der Wielen M; Almagor Y; Sharon O; Levin Y
Vaccine; 2009 Jan; 27(3):454-9. PubMed ID: 19022318
[TBL] [Abstract][Full Text] [Related]
17. [Safety of an influenza-split-vaccine in children].
Schmitt-Grohé S; Banzhoff A; Klaassen B; Zielen S
Klin Padiatr; 2001; 213(6):338-42. PubMed ID: 11713714
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy children aged 6-59 months.
King JC; Cox MM; Reisinger K; Hedrick J; Graham I; Patriarca P
Vaccine; 2009 Nov; 27(47):6589-94. PubMed ID: 19716456
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of neuraminidase monospecific (HEqN2) recombinant influenza vaccine in children.
Beutner KR; Rizzone C; DeMello S; Ogra PL
Dev Biol Stand; 1976; 33():162-70. PubMed ID: 782964
[TBL] [Abstract][Full Text] [Related]
20. [Safety and immunogenicity on three lots of influenza split vaccines among adults].
Zhang ZL; Wang X; Zhu XJ; Zhang Y; Liu Y; Gao ZG; Liang M; Li L; Li JM; Liu RK; Dong XJ; Song GX; Zhang DC; Wang WQ; Han YG; Chen JT
Zhonghua Liu Xing Bing Xue Za Zhi; 2009 Jun; 30(6):583-7. PubMed ID: 19957624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
